Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

Hong Kong Approval Expands Mainlanders’ Access to mRNA Covid Shots
Published on: 2022-12-20
Share to
User Rating: / 0
PoorBest 

Two messenger RNA-based Covid-19 vaccines developed by Germany’s BioNTech were officially registered in Hong Kong as regularly available treatments in the city, elevating the shots’ previous emergency-use approval.

The registration means the vaccines will be accessible to nonresidents of Hong Kong, including visitors from the mainland and other countries, medical professionals in the city told Caixin.

新冠mRNA疫苗复必泰正式获香港注册内地居民可去香港自费接种

12月19日,复星医药发布公告称,控股子公司复星实业(香港)有限公司收到《药品/制品注册证明书》。

公告显示,公司合作引进的mRNA新冠疫苗BNT162b2(以下简称“复必泰BNT162b2”)、原始株/Omicron变异株BA.4-5二价疫苗(以下简称“复必泰二价疫苗”)均获正式注册为中国香港特别行政区药品/制品(生物制品)。

复星医药相关人士表示,上述疫苗在本次注册后,有接种意愿的人士可凭当地医生处方于位于中国香港的医疗机构或诊所接种该等疫苗,使用范围将不再限于当地政府接种计划下的接种。

据了解,mRNA新冠疫苗复必泰(BNT162b2)自2021年3月起在港澳地区作紧急使用, 并纳入政府接种计划,即仅针对香港本地居民才能接种。本次获批成为正式注册药品后,意味着内地居民未来可以去香港自费接种复必泰。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2024 BusinessTianjin.com. All rights reserved.